Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
ZacksBiogen’s (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter’s lead asset, felzartamab.
Biogen’s (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter’s lead asset, felzartamab.